TMCnet News
Bharat Book Bureau: PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022(M2 PressWIRE Via Acquire Media NewsEdge) Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roche's Pegasys and Merck's PegIntron) and ribavirin (e.g., Roche's Copegus and Merck's Rebetol) are used to treat HCV infection. Patients infected with HCV genotype 1 can also have a protease inhibitor added to their combination therapy, such as Merck's Victrelis (boceprevir) or Vertex's Incivek (telaprevir). The entrance of next-generation HCV therapies is expected to fundamentally change the HCV treatment algorithm. GlobalData expects a dramatic shift favoring the uptake of interferon-free regimens due to their more tolerable side-effect profiles and decreased duration of therapy compared with the current standard of care. Highlights Key Questions Answered - What is the fate of Vertex's Incivek and Merck's Victrelis after the launch of next-generation HCV therapies? - What role, if any, will interferon have in the HCV treatment algorithm over the next decade? - Is there demand from physicians for new interferon derivatives? - What metrics do physicians use when evaluating HCV regimens? - Is pill burden a major unmet need in this indication? - Which HCV regimen in development are physicians most excited about? - As direct-acting antivirals (DAAs) overtake the HCV treatment algorithm, is there any need for host-targeting therapies? Key Findings - Patient awareness is anticipated to increase in response to government education and screening initiatives. - Interferon use is predicted to decrease over the next 10 years. - The launch of next-generation, direct-acting antivirals is expected to streamline the HCV treatment algorithm. - The approval of more-tolerable HCV therapies is likely to result in patients deciding to undergo treatment (i.e., decrease in the warehouse effect). Scope - Overview of hepatitis C virus, including epidemiology, etiology, general symptoms from infection, and national vaccination recommendations and guidelines. - Annualized hepatitis C therapeutics market revenue, annual cost of vaccination and treatment usage pattern data from 2012 and forecast for nine years to 2022. - Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the hepatitis C market. - Pipeline analysis: comprehensive data split across different phases, and emerging trends, specifically interferon-free therapies and fixed-dose combinations. - Analysis of the current and future market competition in the global hepatitis C therapeutics market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. To know more : https://www.bharatbook.com/healthcare-market-research-reports-470133/drug-healthcare-global-16.html OR Contact us at : Bharat Book Bureau Tel: +91 22 27810772 / 27810773 Toll Free No for USA/Canada : 1-866-279-8368 Email: [email protected] Website: www.bharatbook.com Follow us on twitter: https://twitter.com/researchbook Follow us on linkedin : http://www.linkedin.com/company/bharat-book-bureau Our Blog : http://blog.bharatbook.com/ . (c) 2014 M2 COMMUNICATIONS |